Latest Filings

Issuer Activity

Insider Overview :: Cardiome Pharma Corp. (T:COM) [?]
Business Focus: Biopharmaceuticals
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.
Recent Price for COM
CAD 2.17 +0.10 (+4.61%)
TSX Delayed 15 minutes
May 17 1535 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 2.70 4.0 N/A 27.06
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 1.18 0.0% 9,164  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 19th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 29/13 Mar 26/13 Grant, Sheila Direct Ownership Common Shares 00 - Opening Balance-Initial SEDI Report 3,900  
Apr 29/13 Mar 26/13 Grant, Sheila Direct Ownership Options 00 - Opening Balance-Initial SEDI Report 297,501  
Apr 29/13 Mar 25/13 Rieder, Robert Direct Ownership Options 52 - Expiration of options -28,827 $12.07
Apr 29/13 Mar 25/13 Lalji, Karim Fatehali Direct Ownership Options 52 - Expiration of options -1,857 $12.07
Mar 22/13 Mar 22/13 Hunter, William L. Direct Ownership Common Shares 10 - Acquisition in the public market 301,026 $0.338
USD
Mar 22/13 Mar 21/13 Hunter, William L. Direct Ownership Common Shares 10 - Acquisition in the public market 198,974 $0.327
USD
Mar 22/13 Mar 21/13 Hunter, William L. Direct Ownership Options 50 - Grant of options 1,000,000 $0.330
Mar 22/13 Mar 21/13 Lalji, Karim Fatehali Direct Ownership Options 50 - Grant of options 125,000 $0.330
Mar 22/13 Mar 21/13 Archibald, Jennifer Direct Ownership Options 50 - Grant of options 75,000 $0.330
Dec 30/12 Dec 27/12 Archibald, Jennifer Direct Ownership Options 52 - Expiration of options -50,000 $11.26
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 19th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 29/13 Mar 25/13 Rieder, Robert Direct Ownership Options 52 - Expiration of options -28,827 $12.07
Apr 29/13 Mar 25/13 Lalji, Karim Fatehali Direct Ownership Options 52 - Expiration of options -1,857 $12.07
Apr 29/13 Mar 26/13 Grant, Sheila Direct Ownership Common Shares 00 - Opening Balance-Initial SEDI Report 3,900  
Apr 29/13 Mar 26/13 Grant, Sheila Direct Ownership Options 00 - Opening Balance-Initial SEDI Report 297,501  
Mar 22/13 Mar 22/13 Hunter, William L. Direct Ownership Common Shares 10 - Acquisition in the public market 301,026 $0.338
USD
Mar 22/13 Mar 21/13 Hunter, William L. Direct Ownership Common Shares 10 - Acquisition in the public market 198,974 $0.327
USD
Mar 22/13 Mar 21/13 Hunter, William L. Direct Ownership Options 50 - Grant of options 1,000,000 $0.330
Mar 22/13 Mar 21/13 Lalji, Karim Fatehali Direct Ownership Options 50 - Grant of options 125,000 $0.330
Mar 22/13 Mar 21/13 Archibald, Jennifer Direct Ownership Options 50 - Grant of options 75,000 $0.330
Dec 30/12 Dec 27/12 Archibald, Jennifer Direct Ownership Options 52 - Expiration of options -50,000 $11.26
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for COM on May 17, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
Robert W. Rieder
Chairman of the Board 		William L. Hunter
President, Chief Executive Officer, Director 		Jennifer Archibald
Chief Financial Officer
Sheila M. Grant
Chief Operating Officer 		Karim Lalji
Chief Commercial Officer 		Donald A. McAfee
Executive Scientist
Joseph Garcia
Corporate Secretary 		   
Company Contact
Address: 6th Floor
6190 Agronomy Rd.
VANCOUVER BC V6T 1Z3
Tel: 1-604-6776905
Website: www.cardiome.com
IR: www.cardiome.com/investors
Business Overview
Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company's clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral).
Competitors with Recent Insider Filings
Transition Therapeutics (T:TTH)
Stem Cell Therapeutics (V:SSS)
 
Cardiome Pharma Corp. Insider Report Only $20.00